PREP

What can we help you find?
[[thumbnail_alt_text]]
Geographic shifts in the HIV epidemic, racial disparities, and the complexities of the medical system all present obstacles to prevention and treatment services.
 
[[thumbnail_alt_text]]
Researchers, advocates, and other stakeholders are urging for care to be expanded to overcome barriers in high-risk populations to address the HIV epidemic, as part of a series published in The Lancet HIV in the USA Series.
[[thumbnail_alt_text]]
In order to eradicate HIV, the researchers said increasing health coverage will be essential. Without that, HIV will continue to spread, and individuals will be unaware of their status.
 
[[thumbnail_alt_text]]
Patients with HIV who were hospitalized with COVID-19 were found to have high proportions of HIV virologic control on antiretroviral therapy.
[[thumbnail_alt_text]]
At the virtual 2020 ASHP Midyear Clinical Meeting and Exhibition, Elyse Tung, PharmD, BCACP, discussed key counseling points for pharmacists to address with patients when prescribing and managing PrEP.
[[thumbnail_alt_text]]
Additional non-oral options could provide more manageable forms of PrEP treatment for patients, potentially increasing global uptake of PrEP in the future.
[[thumbnail_alt_text]]
Further, the study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).
[[thumbnail_alt_text]]
Further, the study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).
[[thumbnail_alt_text]]
This activity is supported by an educational grant from Janssen Therapeutics, division of Janssen Products, LP.
[[thumbnail_alt_text]]
Less than 10% of the people who should be taking pre-exposure prophylaxis for HIV are taking the medications. 

 
[[thumbnail_alt_text]]
Insurance companies are currently investigating the option of modifying which medications they will cover for HIV pre-exposure prophylaxis (PrEP) therapy, with broad implications for patient access.